Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
SURYADEVARA ET AL., 2021. CELL 184(9): 2316-2331.
RESOURCES
Where research scientists come to find up to date resources on antibody discovery against challenging membrane protein targets.
Category: Mapping and Engineering
A Novel Antigenic Site Spanning Domains I and III of the Zika Virus Envelope Glycoprotein Is the Target of Strongly Neutralizing Human Monoclonal Antibodies
GRAHAM ET AL. 2021. J VIROL DOI: 10.1128/JVI.02423-20.
Brain-specific angiogenesis inhibitor 1 is expressed in the Myo/Nog cell lineage
GERHART ET AL. 2020. PLoSONE 15(7):e0234792.
Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics
GILCHUK ET AL. 2020. NATURE BIOMED ENG 4:1030-1043.
Antigenicity, stability, and reproducibility of Zika reporter virus particles for long-term applications
WHITBECK ET AL. 2020. PLoS NEGL TROP DIS 14(11): e0008730.
Transcriptional and clonal characterization of B cell plasmablast diversity following primary and secondary natural DENV infection
WAICKMAN ET AL. 2020. EBIOMED 54:102733
Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcγR interaction on monocytes
FOX, ET AL. 2019. SCI IMMUNOL, 4(32): EAAV5062
Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope
LONG, ET AL. 2019. PNAS DOI: 10.1073/PNAS.1815432116.
Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection
SAPHIRE, ET AL. 2018. CELL 174(4):938-952